1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Congenital Nephrogenic Diabetes Insipidus: new trials by email Literature Review of Congenital Nephrogenic Diabetes Insipidus trials Research Report on Congenital Nephrogenic Diabetes Insipidus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration PB - Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus | Phase 2 | Completed | Mayo Clinic | 36 | 2022-09-01 | 2026-01-27 |
Diabetes Insipidus (1) · Diabetes Insipidus, Nephrogenic (1) · Polycystic Kidney Diseases (1) · Polycystic Kidney, Autosomal Dominant (1)
Abnormalities, Multiple (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1) · Kidney Diseases (1) · Kidney Diseases, Cystic (1) · Male Urogenital Diseases (1) · Pituitary Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Mayo Clinic (1)
United States (1)
Fouad Chebib, MD (1)